Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Psoriasis development criteria more competitive than ever, says GlobalData

The psoriasis (PsO) market has typically been dominated by injectable biologics. However, this segment has become fairly saturated, given the number of different efficacious biologics already available. As a result, drug manufacturers now have no choice but to continue setting and exceeding increasingly high clinical development standards to gain a foothold in this mature field, […]
Read more

Trikafta/Kaftrio continues to be a game-changer for cystic fibrosis patients, says GlobalData

Following the news that Vertex’s Trikafta/Kaftrio has been approved for children ages six to 11 years with cystic fibrosis (CF); Mandana Emamzadeh, PhD, Healthcare Analyst at GlobalData, a leading data and analytics company, offers her view: “Trikafta/Kaftrio has greatly expanded the number of CF-related mutations that are eligible for CFTR modulator treatment across age groups. […]
Read more

Eosinophilic esophagitis market in US set to be worth $1.5 billion by 2030, with limited disease awareness remaining main barrier to growth, says GlobalData

The US eosinophilic esophagitis (EoE) market, valued at $156.7 million in 2020, is projected to grow at a compound annual growth rate (CAGR) of 25.7%, to reach $1.5 billion by 2030. However, despite this impressive growth rate, low diagnosis rates caused by limited disease awareness will continue to keep the diagnosis cases at a low rate, […]
Read more

Improved diagnosis and wider therapeutic options represent key unmet needs in hypothyroidism, says GlobalData

In light of National Thyroid Awareness Month, GlobalData highlights that the lack of awareness around hypothyroidism (also known as ‘underactive thyroid’) is impacting diagnosis rates and limiting investment. The leading data and analytics company notes that only 14%* of Phase I-III clinical trials for hypothyroidism in the last five years were sponsored by pharma companies. […]
Read more

Restrictive Medicare coverage spells continued uncertainty for Aduhelm, says GlobalData

Following the Centers for Medicare & Medicaid Services’ (CMS) announcement of draft guidance on its highly anticipated reimbursement decision regarding Aduhelm (aducanumab) and other future anti-amyloid monoclonal antibody (mAb) products in Alzheimer’s disease (AD); Rose Joachim, Pharma Analyst at GlobalData, a leading data and analytics company, offers her view: “CMS’s decision to limit Medicare reimbursement […]
Read more

Diagnosed incident cases of chronic myeloid leukemia to reach 17,500 by 2030 across 8MM, forecasts GlobalData

The diagnosed incident cases of chronic myeloid leukemia (CML) across the eight major markets (*8MM) are projected to increase from 15,500 cases in 2020 to 17,500 in 2030, equating to an annual growth rate (AGR) of 1.32%, forecasts GlobalData, a leading data and analytics company. GlobalData’s latest report, ‘Chronic Myeloid Leukemia: Epidemiology Forecast to 2030’, […]
Read more

Key pharma players collaborate with tech companies in Singapore to stay competitive, observes GlobalData

AstraZeneca Singapore signed a contract with technology partners Respiree, OncoShot, Thermaiscan, Ubie and Hewlett Packard Enterprise in November 2021 to offer new digital healthcare solutions for chronic conditions such as cancer, diabetes, heart failure, and respiratory diseases to patients. Against this backdrop, pharma companies are under constant pressure to innovate and stay competitive. As a […]
Read more

Primary open angle glaucoma total prevalent cases set to reach 8.84 million in the 7MM by 2030, driven by an aging population, more comorbid conditions, and delayed access to health care facilities, says GlobalData

The burden of total prevalent cases (diagnosed and undiagnosed) of primary open angle glaucoma (POAG) is expected to increase at an annual growth rate (AGR) of 2% from around 7.3 million cases in 2020 to 8.84 million in 2030 in the seven major markets (7MM*), according to GlobalData. The leading data and analytics company notes […]
Read more

Impending regulatory decisions in the atopic dermatitis market, says GlobalData

The FDA has yet to come to a conclusion on the approval of Lilly/Incyte’s JAK1/2 inhibitor Olumiant (baricitinib), AbbVie’s JAK 1 inhibitor Rinvoq (upadacitinib), and Pfizer’s, JAK 1 inhibitor Cibinqo (abrocitinib), the leading data and analytics company notes that competition will likely heighten once these JAK inhibitors become available. Ramla Salad, Pharma Analyst at GlobalData, […]
Read more

Successful FDA EUA of first indigenous combo mAb therapy may boost China’s credibility, says GlobalData

The National Medical Products Administration (NMPA) of China has recently approved Brii Biosciences’ amubarvimab/romlusevimab combination as the first COVID-19 neutralizing antibody combination therapy in the country. The company is currently pursuing emergency use authorization (EUA) from the FDA. If approved, it becomes the first combo antibody therapy from a Chinese company to gain entry into […]
Read more
1 … 53 54 55 56 57 … 110